Market Access Impact (EU5) [PsO]
Eliminating market barriers could lift the last place brand into the middle of the pack
In the EU5 countries, market barriers affect nearly a quarter of psoriasis prescriptions. Most of the brands we surveyed gain or lose a little bit of market share, but one brand is having a much harder time of it. If it can find a way to overcome market barriers, this brand could climb from dead last to somewhere in the middle of the pack.
Find out whether breaking down market barriers can give your brand a boost in Market Access Impact: Psoriasis (EU5).
Based on a survey of 150 dermatologists, the report covers 10 major therapies from AbbVie, Biogen, Celgene, EliLilly, Janssen Cilag, Merck Sharp & Dohme, Napp/Mundipharma, Novartis, and Pfizer. Handy graphs and charts reveal which of 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Top Takeaways
Market Access Impact: Psoriasis (EU5) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access:
We surveyed 150 dermatologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents have
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
In the EU5 countries, market barriers affect nearly a quarter of psoriasis prescriptions. Most of the brands we surveyed gain or lose a little bit of market share, but one brand is having a much harder time of it. If it can find a way to overcome market barriers, this brand could climb from dead last to somewhere in the middle of the pack.
Find out whether breaking down market barriers can give your brand a boost in Market Access Impact: Psoriasis (EU5).
Based on a survey of 150 dermatologists, the report covers 10 major therapies from AbbVie, Biogen, Celgene, EliLilly, Janssen Cilag, Merck Sharp & Dohme, Napp/Mundipharma, Novartis, and Pfizer. Handy graphs and charts reveal which of 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Top Takeaways
- Barriers have a modest effect on surveyed brands: They affect nearly a quarter of prescriptions, but no surveyed brand gains or loses more than 2 percent of its share because of them.
- “Other” brands see significant benefits: In aggregate, brands not surveyed see the largest barrier-related gain, putting them ahead of more than a third of surveyed brands.
- Barriers are holding the last-place brand down: If barriers didn’t exist, the last-place brand would climb to the middle of the pack.
- The barrier effect is uneven: Several barriers have a big effect on a small number of brands, and less of an effect on the rest.
- Many doctors don’t experience barriers at all: 40 percent or more of surveyed doctors don’t experience any barriers with most of the surveyed brands.
- Several brands have perception problems: 14 to 24 percent of surveyed doctors either wouldn’t consider prescribing them or simply don’t know they exist.
- Benepali (etanercept; Biogen)
- Cosentyx (secukinumab; Novartis)
- Enbrel (etanercept; Pfizer)
- Humira (adalimumab; AbbVie)
- Inflectra (infliximab; Pfizer)
- Otezla (apremilast; Celgene)
- Remicade (infliximab; Merck Sharp & Dohme)
- Remsima (infliximab; Napp/Mundipharma)
- Stelara (ustekinumab; Janssen Cilag)
- Taltz (ixekizumab; Eli Lilly)
Market Access Impact: Psoriasis (EU5) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest impact?
- How many doctors prescribe your brand? How many don’t, but would consider it?
- Why don’t doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?
We surveyed 150 dermatologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents have
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with psoriasis in total in the last month
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. WHAT ARE MARKET BARRIERS?
2. ABOUT THIS REPORT
3. ABOUT THE SURVEY
4. BRANDS INCLUDED IN THE SURVEY
5. EXECUTIVE SUMMARY
2. ABOUT THIS REPORT
3. ABOUT THE SURVEY
4. BRANDS INCLUDED IN THE SURVEY
5. EXECUTIVE SUMMARY
